Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Supplemental Mobility

9 novembre 2026 aggiornato da: University of Colorado, Denver

Improving Functional Recovery in Skilled Nursing Facilities Through Supplemental Mobility

This pilot study will evaluate the feasibility of a supplemental mobility intervention, the Safe Transfers And Mobility Program (STAMP). This program will be implemented in patients admitted to skilled nursing facilities (SNFs) following hospitalization. STAMP will be administered by a mobility aide who will support patients in increasing physical activity through walking and transfers outside of structured rehabilitation. Participants will either receive high-intensity rehabilitation (HIR) or usual care rehabilitation, combined with STAMP. The two main aims are: 1) determine the feasibility, acceptability, and safety of STAMP, and 2) evaluate the feasibility and variability of patient physical function outcome measures. The study will provide preliminary data on program delivery and safety to inform the design of a larger trial aimed at identifying the most effective strategies to optimize functional recovery in SNFs.

Panoramica dello studio

Stato

Reclutamento

Condizioni

Intervento / Trattamento

Descrizione dettagliata

A substantial portion of older adults receiving care in skilled nursing facilities (SNFs) do not achieve successful outcomes, with nearly 40% unable to return home and up to 29% experiencing hospital readmission an outcome strongly associated with mortality. A major, modifiable contributor to these poor outcomes is reduced physical function. Although SNFs offer structured rehabilitation to address mobility impairments, its effectiveness is undermined by pervasive sedentary behavior. Up to 96% of patients receiving care in SNFs require assistance with mobility, and despite participating in daily rehabilitation, patients average less than 1,000 steps per day.

Our team conducted an NIH-funded pragmatic cluster randomized trial (R01, AG072693) evaluating high-intensity rehabilitation (HIR) to improve functional recovery. This trial provided a strong foundation and highlighted that high-intensity rehabilitation alone may be insufficient if patients remain inactive outside of scheduled sessions.

The purpose of this study is to determine the feasibility of an interdisciplinary, patient-centered mobility program (STAMP) to address common barriers in SNFs (e.g., staff shortages, safety concerns, limited training) and increase daily activity with support from a mobility aide. This aide will support patients in walking and functional transfers outside of formal therapy sessions, targeting 45 minutes of additional physical activity to complement structured rehabilitation. This study will explore whether STAMP alone or in combination with HIR offers a scalable strategy to improve function. The study will evaluate STAMP implemented in two settings: one with HIR + STAMP and one with usual care + STAMP. Investigators will determine feasibility, acceptability, and safety of STAMP through a convergent parallel mixed methods approach. Secondarily, investigators will evaluate the feasibility and variability of patient physical function outcome measures to inform outcome selection for future trials.

Tipo di studio

Interventistico

Iscrizione (Stimato)

192

Fase

  • Non applicabile

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Luoghi di studio

    • Colorado
      • Aurora, Colorado, Stati Uniti, 80045
        • Non ancora reclutamento
        • University of Colorado Denver, Anschutz Medical Campus
        • Contatto:
    • Texas
      • Frisco, Texas, Stati Uniti, 75034

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

50 anni e precedenti (Adulto, Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Descrizione

Inclusion Criteria:

  • At least 50 years old
  • Admitted to SNF from the hospital
  • Ambulatory at admission with minimal assistance or less

Exclusion Criteria:

  • Contraindications to high-intensity resistance training (per American College of Sports Medicine Exercise Testing and Prescription)
  • Neurological diagnosis (e.g., cerebral vascular accident, multiple sclerosis, Parkinson's disease, traumatic brain injury)
  • Lower extremity weight-bearing precautions that require greater than minimal assistance with ambulation
  • Subsequent SNF admission

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: Non randomizzato
  • Modello interventistico: Assegnazione parallela
  • Mascheramento: Nessuno (etichetta aperta)

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Comparatore attivo: Solita cura

Usual Care SNFs will continue with routine collection and documentation of physical performance outcomes (gait speed, SPPB, Modified Barthel ADL Index) as standard practice. Importantly, the Usual Care SNF including the facility, rehabilitation clinicians, and patients will not have access to i-STRONGER materials.

Sperimentale: High Intensity Rehabilitation

An 8RM is the dose necessary for most effective strength gains in community-dwelling older adults, and is equivalent to 80% of a one repetition max, which is the maximal load needed to voluntarily complete one repetition of a given exercise with proper form. Activities will include strength training, transfer practice, balance training, advanced ADLs. Clinicians will tailor the intervention for each activity to target overload using 8-repetition maximum for resistance training. Other interventions will be performed to muscle failure or inability to complete the final repetition. Failure is the inability to complete a repetition through the full, available range of motion without significant compensation. Further, high-intensity dosing requires continuous, volitional effort from the patient; therefore, incorporation of motivational interviewing strategies across sessions will maximize patient effort and self-efficacy.

Sperimentale: Usual Care and STAMP

Usual Care SNFs will continue with routine collection and documentation of physical performance outcomes (gait speed, SPPB, Modified Barthel ADL Index) as standard practice. Importantly, the Usual Care SNF including the facility, rehabilitation clinicians, and patients will not have access to i-STRONGER materials.

The Safe Transfers and Mobility Program (STAMP) embeds a mobility aide into daily care. STAMP is a patient-centered, scalable approach to extend the benefits of rehabilitation sessions by increasing mobility throughout the day and reinforcing activity between therapy sessions. Core components are: (1) targeting 45 minutes of additional daily physical activity through support with walking and functional mobility tasks; (2) establishing individualized mobility goals collaboratively set by the therapist and patient, based on functional level; (3) delivering progressive activities with walking distances increased by ~30% weekly, adjusted for patient tolerance; and (4) interdisciplinary coordination to incorporate STAMP sessions into routine care with minimal disruption to clinical workflow. Prior work suggests that 45 minutes of STAMP can at least double daily step counts, and increasing walking distance by 30% per week is feasible even for individuals with low baseline function.

Sperimentale: High Intensity Rehabilitation and STAMP

An 8RM is the dose necessary for most effective strength gains in community-dwelling older adults, and is equivalent to 80% of a one repetition max, which is the maximal load needed to voluntarily complete one repetition of a given exercise with proper form. Activities will include strength training, transfer practice, balance training, advanced ADLs. Clinicians will tailor the intervention for each activity to target overload using 8-repetition maximum for resistance training. Other interventions will be performed to muscle failure or inability to complete the final repetition. Failure is the inability to complete a repetition through the full, available range of motion without significant compensation. Further, high-intensity dosing requires continuous, volitional effort from the patient; therefore, incorporation of motivational interviewing strategies across sessions will maximize patient effort and self-efficacy.

The Safe Transfers and Mobility Program (STAMP) embeds a mobility aide into daily care. STAMP is a patient-centered, scalable approach to extend the benefits of rehabilitation sessions by increasing mobility throughout the day and reinforcing activity between therapy sessions. Core components are: (1) targeting 45 minutes of additional daily physical activity through support with walking and functional mobility tasks; (2) establishing individualized mobility goals collaboratively set by the therapist and patient, based on functional level; (3) delivering progressive activities with walking distances increased by ~30% weekly, adjusted for patient tolerance; and (4) interdisciplinary coordination to incorporate STAMP sessions into routine care with minimal disruption to clinical workflow. Prior work suggests that 45 minutes of STAMP can at least double daily step counts, and increasing walking distance by 30% per week is feasible even for individuals with low baseline function.

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Usual Gait Speed
Lasso di tempo: Admission into rehabilitation and discharge from rehabilitation, which would be an approximate average of 14 days

Gait speed will be measured in meters/second using the time it takes to walk a 4-meter path at usual speed using a stopwatch. Completion rates will be collected. Within site pre- to post- STAMP changes will be assessed. Higher gait speed indicates better outcome.

Admission into rehabilitation and discharge from rehabilitation, which would be an approximate average of 14 days

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Feasibility of Intervention Measure (FIM)
Lasso di tempo: At end of STAMP phase, approximately 8 months

Feasibility of Intervention (FIM) will be collected from SNF Providers to assess feasibility. The FIM is a 4-item survey rated on a 5-point Likert scale (1=completely disagree to 5=completely agree), with higher average scores indicating greater feasibility.

At end of STAMP phase, approximately 8 months
STAMP Session Adherence Rate
Lasso di tempo: Beginning of STAMP phase to end of STAMP phase, approximately 8 months

Of all enrolled patients, percent completing ≥ 80% of sessions attempted by mobility aide

Beginning of STAMP phase to end of STAMP phase, approximately 8 months
Modified 30 Second Sit to Stand
Lasso di tempo: Admission into rehabilitation and discharge from rehabilitation, which would be an approximate average of 14 days

The Modified 30 second sit to stand test (m30STS) counts the number of stands from a chair completed in 30 seconds, which allows for upper extremity use on the armrests of a chair. The score is the total number of stands completed in 30 seconds; more than halfway up at the end of 30 seconds counts as a stand. Completion rates will be collected. Within site pre- to post- STAMP changes will be assessed. Higher scores indicate better outcomes.

Admission into rehabilitation and discharge from rehabilitation, which would be an approximate average of 14 days
Number of Rehospitalizations
Lasso di tempo: Up to 8 months of Pre-STAMP phase and 8 months of STAMP phase

Number of re-hospitalizations during SNF stay.

Up to 8 months of Pre-STAMP phase and 8 months of STAMP phase
STAMP Intervention Fidelity
Lasso di tempo: Beginning of STAMP phase to end of STAMP phase, approximately 8 months

Percent of mobility aides achieving an average of ≥80% fidelity across study assessments. A formally trained site champion or research team member will measure STAMP fidelity on at least 2 patients per mobility aide each quarter.

Beginning of STAMP phase to end of STAMP phase, approximately 8 months
Theoretical Framework of Acceptability (TFA)
Lasso di tempo: At month 8 of STAMP phase

Theoretical Framework of Acceptability (TFA) will be collected from SNF Providers to assess acceptability of the STAMP intervention. The TFA is a survey, which includes 8 items rated 1-5 on a Likert scale and summed (higher scores indicate greater acceptability).

At month 8 of STAMP phase
Pittsburgh Rehabilitation Participation Scale (PRPS)
Lasso di tempo: Every patient encounter during STAMP phase

Patient acceptability of the STAMP intervention will be assessed by mobility aides using the PRPS. The PRPS is a validated, single question, 6-point Likert-scale, rated by the mobility aide, that measures effort and participation. Higher score indicates more acceptability.

Every patient encounter during STAMP phase
Change in Step Count
Lasso di tempo: Admission into rehabilitation and discharge from rehabilitation, which would be an approximate average of 14 days

Change in daily step count from admission to discharge.

Admission into rehabilitation and discharge from rehabilitation, which would be an approximate average of 14 days
Proportion of Patients with Increased Step Count
Lasso di tempo: Admission into rehabilitation and discharge from rehabilitation, which would be an approximate average of 14 days

Of all enrolled patients, proportion achieving ≥20% increase in daily step count from admission to discharge.

Admission into rehabilitation and discharge from rehabilitation, which would be an approximate average of 14 days
Change in Short Physical Performance Battery (SPPB)
Lasso di tempo: Admission into rehabilitation and discharge from rehabilitation, which would be an approximate average of 14 days

The SPPB is comprised of 3 tasks: a hierarchical standing balance test (side-by-side, semi-tandem, and tandem), a 4-meter usual gait speed, and a 5-time sit-to-stand from a standardized chair. Each subtask is scored (based on time) from 0-4 points and then summarized into a total score of 0-12 points, where 12 points represents the highest performance. Completion rates and within site pre- to post-STAMP differences will be assessed.

Admission into rehabilitation and discharge from rehabilitation, which would be an approximate average of 14 days
Change in Modified Barthel ADL Index (MBI)
Lasso di tempo: Admission into rehabilitation and discharge from rehabilitation, which would be an approximate average of 14 days

The MBI assesses the ability to perform basic Activities of Daily Living (ADL) tasks. Total score range is 0-100. Total score is commuted by summing dependence across 10 ADL tasks: chair/bed transfers, ambulation, stair climbing, toilet transfers, bowel control, bladder control, bathing, dressing, personal hygiene (grooming), and feeding. Higher scores indicate increased independence. Completion rates and within site pre- to post-STAMP differences will be assessed.

Admission into rehabilitation and discharge from rehabilitation, which would be an approximate average of 14 days

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Sponsor

Collaboratori

Investigatori

  • Investigatore principale: Jennifer Stevens-Lapsley, PT, PhD, University of Colorado, Denver

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

1 ottobre 2026

Completamento primario (Stimato)

1 marzo 2028

Completamento dello studio (Stimato)

1 maggio 2028

Date di iscrizione allo studio

Primo inviato

9 settembre 2026

Primo inviato che soddisfa i criteri di controllo qualità

8 ottobre 2026

Primo Inserito (Effettivo)

13 ottobre 2026

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

10 novembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

9 novembre 2026

Ultimo verificato

1 novembre 2026

Maggiori informazioni

Termini relativi a questo studio

Altri numeri di identificazione dello studio

  • 26-0207
  • 1R21AG095336-01A1 (Sovvenzione/contratto NIH degli Stati Uniti)

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

SÌ

Descrizione del piano IPD

The study team guarantees that any and all data collected as part of this project will be released in accordance with standard data sharing policies and procedures to validate research findings if requested. Data will be made available in a timely manner to the broader scientific community, and will be complete, and as accurate as possible. All data released will be de-identified, with no information that could be linked to any study subjects, or participating study practices to ensure the confidentiality of all subjects and practices. If necessary, a data use agreement will be established.

Periodo di condivisione IPD

The data will be available starting 1 year after primary study publication and ending 2 1/2 years after publication.

Criteri di accesso alla condivisione IPD

Data will be made available upon reasonable written request to the study team. The PI, Dr. Jennifer Stevens-Lapsley will review requests.

Tipo di informazioni di supporto alla condivisione IPD

  • STUDIO_PROTOCOLLO
  • LINFA
  • ICF

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .